Skip to content

Characteristics and outcomes of patients with advanced or metastatic non-small cell lung cancer harboring a HER2-activating mutation: a real-world retrospective cohort study using a US clinico-genomic database.

Nov 2026 · Lung Cancer · Vol 222, pp. 109677 · 0 citations · 27 references
Medicine

Abstract

INTRODUCTION Human epidermal growth factor receptor 2 (HER2/ERBB2) mutated non-small cell lung cancer (NSCLC) is associated with poor prognosis and limited treatment options.

Methods

This retrospective cohort study used electronic health records from US academic and community cancer centers to describe characteristics and treatments of patients with HER2-mutated locally advanced/metastatic NSCLC initiating first-line (1 L) therapy between January 1, 2015, and March 31, 2024, in a real-world setting. Endpoints included real-world progression-free survival (rwPFS) and overall survival (OS) by line of therapy and in subgroups of interest.

Results

Of 158 patients included (median age 69 years, 43.0% with Y772_A775dup [YVMA] mutation), 50.6% had ≥ 2 lines of therapy. Common 1 L therapies were chemotherapy + immune checkpoint inhibitor (ICI; 36.1%) and chemotherapy (27.8%); common second-line (2 L) therapies were ICI (23.8%), chemotherapy + ICI (16.3%), and HER2-targeted antibody-drug conjugate (ADC; 16.3%). Median rwPFS/OS was 5.7/17.5, and 4.3/11.2 months, following initiation of 1 L and 2 L treatment, respectively. Median rwPFS ranged from 4.4 to 8.9 months and median OS from 15.7 to 16.0 months, following initiation of 1 L chemotherapy with or without ICI. Median rwPFS following initiation of 2 L treatment with ICI ± chemotherapy, chemotherapy ± monoclonal antibody, or HER2-targeted ADC ranged from 3.0 to 4.7 months, and OS from 10.8 to 23.4 months. Outcomes appeared to be descriptively inferior in patients with YVMA mutations versus other subgroups.

Conclusions

Overall outcomes were unsatisfactory, including in patients who had received chemotherapy ± ICI or HER2-targeted ADC in any line, highlighting the need for more effective targeted therapies.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.